Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Gross Profit (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Gross Profit for 4 consecutive years, with $812000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit fell 11.64% to $812000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.6 million, a 6.81% increase, with the full-year FY2024 number at $2.4 million, down 5.44% from a year prior.
  • Gross Profit was $812000.0 for Q3 2025 at Orchestra BioMed Holdings, up from $790000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $1.1 million in Q1 2023 to a low of $195000.0 in Q4 2024.
  • A 4-year average of $717066.7 and a median of $812000.0 in 2025 define the central range for Gross Profit.
  • Biggest YoY gain for Gross Profit was 152.49% in 2023; the steepest drop was 79.52% in 2023.
  • Orchestra BioMed Holdings' Gross Profit stood at $1.0 million in 2022, then crashed by 79.52% to $215000.0 in 2023, then dropped by 9.3% to $195000.0 in 2024, then surged by 316.41% to $812000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Gross Profit are $812000.0 (Q3 2025), $790000.0 (Q2 2025), and $824000.0 (Q1 2025).